首页> 外文期刊>Investigative ophthalmology & visual science >Identification of disease-causing mutations in autosomal dominant retinitis pigmentosa (adRP) using next-generation DNA sequencing.
【24h】

Identification of disease-causing mutations in autosomal dominant retinitis pigmentosa (adRP) using next-generation DNA sequencing.

机译:使用下一代DNA测序鉴定常染色体显性遗传性视网膜色素变性(adRP)的致病突变。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine whether massively parallel next-generation DNA sequencing offers rapid and efficient detection of disease-causing mutations in patients with monogenic inherited diseases. Retinitis pigmentosa (RP) is a challenging application for this technology because it is a monogenic disease in individuals and families but is highly heterogeneous in patient populations. RP has multiple patterns of inheritance, with mutations in many genes for each inheritance pattern and numerous, distinct, disease-causing mutations at each locus; further, many RP genes have not been identified yet. METHODS: Next-generation sequencing was used to identify mutations in pairs of affected individuals from 21 families with autosomal dominant RP, selected from a cohort of families without mutations in "common" RP genes. One thousand amplicons targeting 249,267 unique bases of 46 candidate genes were sequenced with the 454GS FLX Titanium (Roche Diagnostics, Indianapolis, IN) and GAIIx (Illumina/Solexa, San Diego, CA) platforms. RESULTS: An average sequence depth of 70x and 125x was obtained for the 454GS FLX and GAIIx platforms, respectively. More than 9000 sequence variants were identified and analyzed, to assess the likelihood of pathogenicity. One hundred twelve of these were selected as likely candidates and tested for segregation with traditional di-deoxy capillary electrophoresis sequencing of additional family members and control subjects. Five disease-causing mutations (24%) were identified in the 21 families. CONCLUSION: This project demonstrates that next-generation sequencing is an effective approach for detecting novel, rare mutations causing heterogeneous monogenic disorders such as RP. With the addition of this technology, disease-causing mutations can now be identified in 65% of autosomal dominant RP cases.
机译:目的:确定大规模并行的下一代DNA测序能否快速有效地检测单基因遗传性疾病患者的致病突变。色素性视网膜炎(RP)是这项技术的一项具有挑战性的应用,因为它是个体和家庭中的单基因疾病,但在患者人群中异质性很高。 RP具有多种遗传模式,每个遗传模式的许多基因都有突变,并且每个基因座都有许多独特的致病突变。此外,尚未发现许多RP基因。方法:采用下一代测序技术鉴定了21个常染色体显性RP家族受影响个体的突变,这些家族选自“普通” RP基因无突变的家族。用454GS FLX Titanium(Roche Diagnostics,Indianapolis,IN)和GAIIx(Illumina / Solexa,San Diego,CA)平台对1000个靶向46个候选基因的249,267个独特碱基的扩增子进行了测序。结果:454GS FLX和GAIIx平台的平均序列深度分别为70x和125x。鉴定并分析了9000多个序列变体,以评估致病性的可能性。其中一百一十二被选为可能的候选者,并通过传统的双脱氧毛细管电泳测序对其他家庭成员和对照对象进行分离测试。在21个家庭中鉴定出5个致病突变(占24%)。结论:该项目证明了下一代测序是一种有效的方法,可以检测导致异源单基因疾病(例如RP)的新型罕见突变。通过添加该技术,现在可以在65%的常染色体显性RP病例中识别出致病突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号